Search All Tech Briefings

Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available. Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 54 Results

Clear All Filters

Title	Intervention	Indication	Therapeutic Area	Year	Actions
Ribociclib (Kisqali) and fulvestrant for advanced HR positive, HER2‐negative breast cancer in postmenopausal women, first or second line	Fulvestrant (Faslodex) , Ribociclib (Kisqali; LEE-011; ribociclib succinate)	Breast cancer	Breast Cancer	2017	View \| Download
Retifanlimab with chemotherapy for previously untreated metastatic non-small-cell lung cancer	Endocrine therapy , Ribociclib (Kisqali; LEE-011; ribociclib succinate)	Breast cancer , Non-small-cell lung cancer (NSCLC)	Breast Cancer , Lung and Respiratory Cancer	2024	View \| Download
Pertuzumab and trastuzumab (fixed-dose combination) in addition to chemotherapy for breast cancer	Pertuzumab and Trastuzumab (Phesgo; RO7198574) (fixed dose combination: Trastuzumab; Pertuzumab)	Breast cancer	Breast Cancer	2019	View \| Download
Pembrolizumab with chemotherapy for HR+/HER2- locally recurrent inoperable or metastatic breast cancer	Chemotherapy , Pembrolizumab (Keytruda; MK-3475)	Breast cancer	Breast Cancer	2023	View \| Download
Pembrolizumab in combination with neoadjuvant chemotherapy and adjuvant endocrine therapy for early-strage breast cancer	Pembrolizumab (Keytruda; MK-3475)	Breast cancer	Breast Cancer	2021	View \| Download
Pembrolizumab in addition to chemotherapy for locally recurrent, inoperable or metastatic triple-negative breast cancer - first line	Pembrolizumab (Keytruda; MK-3475)	Breast cancer	Breast Cancer	2018	View \| Download
Pembrolizumab in addition to Chemotherapy for Locally Advanced, Non-Metastatic Triple Negative Breast Cancer – neoadjuvant, first line	Pembrolizumab (Keytruda; MK-3475)	Breast cancer	Breast Cancer	2018	View \| Download
Pembrolizumab (Keytruda) for triple negative breast cancer	Pembrolizumab (Keytruda; MK-3475)	Breast cancer	Breast Cancer	2017	View \| Download
Palbociclib with trastuzumab with or without pertuzumab and endocrine therapy for HR+/HER2+ metastatic breast cancer	Palbociclib (Ibrance; PD-0332991) , Trastuzumab (Herceptin; RG-597)	Breast cancer	Breast Cancer	2023	View \| Download
Palbociclib for breast cancer - post neoadjuvant therapy	Palbociclib (Ibrance; PD-0332991)	Breast cancer	Breast Cancer	2020	View \| Download